Investor Relations
Focus on the bottleneck of isotope supply and build a high-performance, efficient, and replicable domestically-produced radionuclide technology system.
Industry-driven demand
The demand for radiopharmaceuticals is growing rapidly, with the global radiopharmaceutical market expected to reach $11.9 billion by 2030, and China's market CAGR reaching 19.7%, making isotope supply a key limiting factor.
Core technological barriers
Independently developed high-current electronic accelerator with a power of 200kW (the highest among similar international models), costing only one-sixth of foreign counterparts, forming domestic substitution capability.
Clear business model
Cash flow can be generated in the short, medium, and long term, covering irradiation services, isotope production, and nuclear medicine pipelines; the three-stage business structure ensures continuous cash generation.
Market Size and Growth
The global nuclear medicine market is growing rapidly, with the Chinese market growing even faster, and the shortage of medical isotopes is creating a hundred-billion-level industry opportunity.
Global nuclear medicine market size in 2030
2021 $4.4B, CAGR 11.8%
2027 China nuclear medicine market size
77 billion yuan in 2022, CAGR 19.7%
Total financing in the nuclear medicine field in 2023
A total of 17 financing events occurred throughout the year
China market potential in 2030
Nuclear medicine diagnosis and treatment full industry chain
Supply and demand gap of nuclides
| Nuclide | Global demand | Domestic demand | Global production capacity | Supply and demand situation |
|---|---|---|---|---|
| Ac-225 | >500 Ci/year | >100 Ci/year | Only 1.7 Ci/year | The supply gap is extremely large |
| Mo-99 | 600,000 Ci/year | 20,000 Ci/year | Centralized supply of reactors | 80% of domestic demand relies on imports |
| Lu-177 | 50,000 Ci/year | 1000 Ci/year | Monopoly of a few suppliers | 95% of domestic demand relies on imports |
policy window
Medium- and Long-Term Development Plan for Medical Isotopes (2021-2035)
Eight ministries jointly issued a statement, clarifying that by 2035, independent supply of key medical isotopes will be achieved.
Reform of Separate Permits and Licenses
The approval authority for radioactive drugs is delegated to the provincial level, shortening the market launch cycle of nuclear drugs and accelerating the industrialization process.
Decentralization of PET-CT configuration approval authority
The approval authority for the allocation of large medical equipment is decentralized, promoting the clinical adoption of radiopharmaceuticals and the release of terminal demand.
Commercialization path
Short-term: Industrial irradiation
Industrial irradiation and accelerator equipment output, annual revenue of 20 to 30 million, quickly forming basic cash flow.
Mid-term: Mass production of isotopes
Achieve mass production supply of isotopes by 2026, simultaneously promote the development of FLASH radiotherapy equipment, serving nuclear medicine companies and research institutions.
Long-term: CRDMO platform
Build a nuclear drug CRDMO platform and self-developed pipeline, providing one-stop services from isotope supply to RDC research and development, and become an industry leader.